{
  "id": 4886446,
  "title": "SAT dismisses Omaxe appeal against SEBI order over financial statement irregularities",
  "url": "https://urgent.news/2026/09/01/sat-dismisses-omaxe-appeal-against-sebi-order-over-financial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-01T15:22:16.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/sat-dismisses-omaxe-appeal-against-sebi-order-over-financial-statement-irregularities/article71415614.ece"
  },
  "original_language": "en",
  "account": "The Securities Appellate Tribunal (SAT) recently declined to entertain an appeal from real estate company Omaxe against a Securities and Exchange Board of India (SEBI) order pertaining to suspected irregularities in the company's financial statements. The dispute dates back to July 2024, when SEBI barred Omaxe, its chairman Rohtas Goel, managing director Mohit Goel, and three additional entities from participating in the securities market for a duration of two years. Furthermore, SEBI imposed penalties totaling ₹47 lakh on 16 entities, including the six entities barred from market access. Individual penalties ranged from ₹1 lakh to ₹7 lakh and were to be settled within 45 days. The regulatory actions stemmed from a complaint alleging that Omaxe engaged in fraudulent transactions, misappropriated funds, misrepresented its financials, and overstated its turnover. SEBI's investigation spanned from April 1, 2018, to March 31, 2021, encompassing the fiscal years 2018-19, 2019-20, and 2020-21. The entities were alleged to have acted together in a fraudulent scheme masquerading as legitimate transactions for Omaxe's benefit, despite the company suffering losses. The transactions were also purportedly classified as lending activities, aimed at propelling Omaxe's share prices over a three-year period. SEBI contended that the company had distorted its financial statements through various elements, such as revenue, debtors, advances, and expenses during the three financial years. The regulator claimed that this extensive misrepresentation of Omaxe's financials directly or indirectly contributed to manipulating the company's share price and maintaining the collateral value pledged by its promoters against loans. Moreover, SEBI asserted that the fraud was not disclosed to Omaxe's shareholders, misleading them to retain their investments or interact with the company's securities. Furthermore, the falsification of the company's books and accounts also deceived investors in the securities market.",
  "summary": "Tribunal upholds market ban and penalties imposed by SEBI on company, promoters and other entities",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}